Guaranteeing better than standard of care for patients in the control arm and offering better efficacy analyses are among ideas the FDA floated to boost participation in trials of orphan drug candidates, which typically are difficult to enroll.
Guaranteeing better than standard of care for patients in the control arm and offering better efficacy analyses are among ideas the FDA floated to boost participation in trials of orphan drug candidates, which typically are difficult to enroll.